Effect of Lidocaine in Reducing Opioids Requirement in Day Care Surgery
Efficacy of Lidocaine in Decreasing Perioperative Analgesic Opioids Requirement After Ambulatory Surgery
1 other identifier
interventional
80
1 country
1
Brief Summary
- 1.\*Reduced opioid consumption
- 2.\*Decreased pain scores
- 3.\*Fewer opioid-related side effects
- 4.\*Improved patient satisfaction
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3 pain
Started Nov 2023
Shorter than P25 for phase_3 pain
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 5, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 10, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 10, 2024
CompletedFirst Submitted
Initial submission to the registry
November 30, 2024
CompletedFirst Posted
Study publicly available on registry
December 5, 2024
CompletedDecember 10, 2024
December 1, 2024
6 months
November 30, 2024
December 5, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Peri-operative pain
Visual Analog pain scale to rate pain scale comprises 0 to 10 score 0 minimum to 10 Maximum
at 2 hours, 4 hours, 6 hours
Study Arms (2)
Intervention group
ACTIVE COMPARATORintervention group recieve inj lidocaine
Control group
PLACEBO COMPARATORcontrol group receive Normal saline
Interventions
1. \_Lidocaine 2% provides rapid and effective local anesthesia for minor surgical procedures, such as biopsies, excisions, and suturing. 2. \_Pain relief\_: Lidocaine 2% has been shown to provide significant pain relief in patients with acute pain, such as post-operative pain, trauma, and burns. 3. \_Reducing pain intensity\_: Lidocaine 2% has been shown to reduce pain intensity by 30-50% in various clinical studies.
Eligibility Criteria
You may qualify if:
- ASA 1 and 2
- patient age between 18 and 65 years
- Patient undergoing ambulatory surgeries
You may not qualify if:
- Pregnant women
- Allergic to Lidocaine Patient who had fever and treated with antibiotic and steroid in last month
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Liaquat National Hospital and Medical College
Karachi, Sindh, Pakistan
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hanesh Tanwani Dr Hanesh Tanwani
Liaquat National Hospital and Medical College
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 30, 2024
First Posted
December 5, 2024
Study Start
November 5, 2023
Primary Completion
May 10, 2024
Study Completion
May 10, 2024
Last Updated
December 10, 2024
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will not share
\*Informed consent\*: Participants may not have provided informed consent for their data to be shared, which could raise ethical concerns. Patient confidentiality\*: Sharing IPD could compromise patient confidentiality and anonymity, potentially harming participants or their families.